EUCTR2008-000145-58-ES进行中（未招募）1 期
Estudio internacional multicéntrico, doble ciego, aleatorizado, en grupos paralelos, con control histórico, de conversión a monoterapia, para evaluar la eficacia y seguridad de brivaracetam en pacientes (= 16 a 75 años de edad) que sufran crisis de inicio parcial con o sin generalización secundaria.(An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (= 16 to 75 years old) with partial onset seizures with or without secondary generalization).
CB Pharma S.A.0 个研究点目标入组 62 人开始时间: 2008年5月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •An IEC/IRB approved written informed consent signed and dated by the subject or by parent(s) or legal representative. The consent form or a specific assent form, where required, will be signed and dated by minors.
- •Subjects from 16 to 75 years, both inclusive. Subjects under 18 years may only be included where permitted legally and ethically accepted.
- •Subjects with a body weight = 45 kg.
- •Female subjects without childbearing potential (pre-menarcheal, post-menopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least 30 µg [or 50 µg ethinylestradiol per intake if associated with carbamazepine (or other strong enzyme inducers e.g. oxcarbazepine)] must be used in conjunction with a barrier method. Monogamous relationship with vasectomized partner or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Sexual inactivity might be accepted on a case-by-case basis.
- •Subject/legally acceptable representative considered as reliable and capable of adhering to the protocol (e.g. able to understand and complete diaries), visit schedule or medication intake according to the judgment of the Investigator.
- •Well-characterized partial onset seizures according to the ILAE classification (1981) or focal epilepsy or epileptic syndrome according to the ILAE classification (1989).
- •Presence of an EEG compatible with the clinical diagnosis of focal epilepsy in the last 5 years. If an EEG has not been performed within the last 5 years, a Baseline EEG must be performed before Visit 3.
- •Presence of a brain CT Scan or MRI performed within the last 2 years. If a CT Scan or MRI has not been performed within the last 2 years, a Baseline exam must be performed before Visit 3.
- •Subjects with a history of inadequately controlled partial onset seizures that may be classified as simple or complex whether or not secondarily generalized (type I seizures according to the ILAE classification, 1981).
- •Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not secondarily generalized per 4 weeks during the 8-week Baseline Period. (NOTE: Aura is a subjective ictal phenomenon, usually visual, visceral or auditory, that in a given subject may precede an observable seizure. When it occurs by itself it constitutes a simple partial sensory seizure. Auras followed by an observable seizure should only be counted as one event and receive the ILAE code of the observable seizure while stand-alone auras should be counted as a seizure and receive the corresponding ILAE code (1981)).
- •Subjects must be on a stable dose of at least 1 but no more than 2 concomitant AEDs for at least 4 weeks before Baseline (Visit 1) and expected to remain on a stable dose until the tapering period commences.
- •If a second AED is taken, its dose must be = 50% of the minimum recommended maintenance dose approved in the US for at least 4 weeks before Baseline (Visit 1).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects fo
排除标准
- •Seizure type IA simple partial non-motor as only seizure type.
- •History or presence of seizures occurring too frequently or indistinctly separated to be reliably counted, during the 6 months preceding Visit 1 or during Baseline.
- •History or presence of status epilepticus during the 1 year preceding Visit 1 or during Baseline.
- •History or presence of pseudo-seizures.
- •Subjects on felbamate with less than 18 months continuous exposure before Visit 1. Subjects having been on felbamate are eligible if the combined duration of treatment and wash-out is = 18 months.
- •Subjects currently on vigabatrin. Subjects having been on vigabatrin if no visual fields examination report available including standard static (Humphrey or Octopus) or kinetic perimetry (Goldman) or if results of these examinations are abnormal.
- •Subjects who have received treatment with phenobarbital or primidone within 3 months prior to Visit 1 and subjects who have received treatment with benzodiazepines within 1 month prior to Visit 1. Subjects with VNS are excluded unless their device has been documented to be inactivated for at least 28 days prior to Visit 1.
- •Subjects taking any drug with possible relevant CNS effects except if stable from at least 1 month before Visit 1 and expected to be kept stable during the study.
- •Subjects taking any drug that may significantly influence the metabolism of BRV (CYP2C or CYP3A potent inducers/inhibitors) except if the dose has been kept stable at least one month before Visit 1, and is expected to be kept stable during the study.
- •History of cerebrovascular accident (CVA), including transient ischemic attack (TIA), in the last 6 months.
- •Subjects suffering from severe cardiovascular disease or peripheral vascular disease.
- •Presence of any sign (clinical or imaging techniques) suggesting rapidly progressing (i.e. not expected to stay stable during trial participation) brain disorder or brain tumor. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable.
- •Any clinical conditions (e.g. bone marrow depression, chronic hepatic disease and/or severe renal impairment) which impair reliable participation in the trial or necessitate the use of medication not allowed by protocol.
- •Presence of a terminal illness.
- •Presence of a serious infection.
- •Subjects with history of severe adverse hematologic reaction to any drug.
- •Subjects suffering from severe disturbance of haemostasis. Impaired hepatic function: ALT/SGPT, AST/SGOT, alkaline phosphatase, gammaGT values of more than three times the upper limit of the reference range. A result of gammaGT exceeding 3 times the upper limit can only be accepted if attributable to hepatic enzyme induction caused by concomitant antiepileptic treatment and other hepatic enzymes are below 3 times the upper limit of the reference range.
- •Subjects having clinically significant deviations from reference range values for laboratory parameters: creatinine clearance calculated < 50 mL/min, platelets < 100,000/µL, or neutrophil cells < 1,800/µL).
- •Clinically significant ECG abnormalities according to the Investigator.
- •History of suicide attempt.
- •Ongoing psychiatric disease other than mild controlled disorder.
- •Subjects who are institutionalized due to judicial reasons.
- •Known allergic reaction or intolerance to pyrrolidone derivatives and/or investigational product excipients (BRV excipients are as follows: Croscarmellose sodium, lactose, beta cyclodextrin, ma
研究者
相似试验
进行中（未招募）
不适用
Estudio internacional multicéntrico, doble ciego, aleatorizado, de grupos paralelos, con control activo y de 12 meses de duración para comparar la eficacia y seguridad de 0.5 mg y 1.25 mg de fingolimod (FTY720) administrado por vía oral una vez al día respecto a interferon Beta-1a (Avonex®) administrado por vía i.m una vez a la semana, en pacientes con esclerosis múltiple remitente-recurrente - D2302Esclerosis múltiple remitente-recurrenteEUCTR2006-000704-17-ESovartis Farmacéutica, S.A.1,275
进行中（未招募）
1 期
Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de liberación prolongada (ER) y el laropiprant (ERN/LRPT) en pacientes con dislipidemia. A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with Dyslipidemia;Dyslipidemia. DislipidemiaMedDRA version: 9 Level: LLT Classification code 10058108 Term: DyslipidaemiaEUCTR2009-012772-27-ESMerck & Co., Inc.1,125
进行中（未招募）
1 期
Estudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo y de 16 semanas de duración para comparar la eficacia y la seguridad de UT-15C en comprimidos orales de liberación prolongada en combinación con un antagonista del receptor de la endotelina y/o con un inhibidor de la fosfodiesterasa-5 en sujetos con hipertensión arterial pulmonarA 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension - FREEDOM-CHAP idiopática o familiar incluyendo HAP asociada a:1) Uso de un inhibidor del apetito2) Corticircuito sistémico-pulmonar congénito corregido (corrección = 5 años)3) HAP asociada a enfermedad del tejido conjuntivo vascular4) HIVMedDRA version: 8.1Level: PTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-000800-17-ESnited Therapeutics Corporation300
进行中（未招募）
不适用
?Estudio internacional, multicéntrico, doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia, la seguridad y la tolerabilidad de MK-0736 añadido al tratamiento en curso con un inhibidor de la enzima convertidora de la angiotensina (IECA) o con un antagonista del receptor de la angiotensina (ARA) en pacientes con diabetes e hipertensión?A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of MK-0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension - MK-0736 Dose Ranging StudyEUCTR2008-004831-39-ESMerk & Co., Inc567
进行中（未招募）
不适用
ESTUDIO MULTINACIONAL, MULTICÉNTRICO, DOBLE CIEGO, ALEATORIZADO Y DE GRUPOS PARALELOS PARA COMPARAR LA SEGURIDAD Y LA EFICACIA DE 200 mg DE PAR-101 CADA 12 HORAS CON 125 mg DE VANCOMICINA CADA 6 HORAS DURANTE DIEZ DÍAS EN SUJETOS CON DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILEA multi-national, multi-centre, double-blind, randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects with Clostridium Difficile-associated diarrhea - A double-blind, randomised study of PAR-101 vs vancomycin in CDADDIARREA ASOCIADA A CLOSTRIDIUM DIFFICILEClostridium difficile associated diarrhoea (CDAD)MedDRA version: 8.1Level: LLTClassification code 10012748Term: Diarrhoea, Clostridium difficileEUCTR2006-004291-12-ESPar Pharmaceutical, Inc.664